Application of C5orf24 protein in tuberculosis diagnostic reagents

The method of capturing tuberculosis antigen by recombinant C5orf24 protein has solved the problem of insufficient sensitivity and specificity of tuberculosis diagnosis in the prior art, and achieved efficient and low-cost tuberculosis detection, which significantly improved the accuracy and sensitivity of the diagnosis.

CN117567587BActive Publication Date: 2024-12-03BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311453918.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-03
Publication Date
2024-12-03
Estimated Expiration
2043-11-03

AI Technical Summary

Technical Problem

The existing tuberculosis diagnosis technology has insufficient detection, insufficient reliability, high cost and susceptible to environmental impact, and the cure rate of multidrug-resistant tuberculosis is low, and there is a lack of high sensitivity and good specificity detection methods.

Method used

Tuberculosis antigen is captured by recombinant C5orf24 protein, and its specific and efficient capture capability is used to develop detection kits to achieve rapid and accurate detection of tuberculosis antigens.

Benefits of technology

It improves the sensitivity and specificity of tuberculosis diagnosis, reduces the detection cost, and provides a high-sensitivity and specific tuberculosis antigen detection method, which can diagnose tuberculosis in a timely and accurate manner.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004529828020000071
    Figure BDA0004529828020000071
  • Figure BDA0004529828020000081
    Figure BDA0004529828020000081
Patent Text Reader

Abstract

The present invention belongs to the field of tuberculosis diagnosis, and specifically relates to an application of a C5orf24 recombinant protein in tuberculosis diagnosis. The present invention utilizes the ability of C5orf24 protein to simultaneously capture multiple tuberculosis antigens in tuberculosis patient specimens, and detects the ability to capture and bind antigens by recombinant C5orf24 protein disease expression and purification. The C5orf24 recombinant protein prepared by the present invention has the characteristics of being able to specifically and efficiently capture multiple tuberculosis antigens.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of tuberculosis diagnosis, and specifically relates to an application of C5orf24 protein in a tuberculosis diagnostic reagent. Background Art

[0002] Tuberculosis is a chronic infectious disease caused by the intracellular bacterial pathogen Mycobacterium tuberculosis. Due to the unique pathogenic characteristics of Mycobacterium tuberculosis and its prevalence and transmission mode, especially the emergence of drug-resistant Mycobacterium tuberculosis and cross-infection with human immunodeficiency virus (HIV) in recent years, the prevalence of tuberculosis has once again shown an upward trend. Mycobacterium tuberculosis is an intracellular infectious bacterium. It is one of the most successful pathogens and has evolved various strategies to adapt to host cells and evade immune surveillance. After entering the human body through the respiratory tract, Mycobacterium tuberculosis mainly parasitizes in macrophages and uses a variety of strategies to evade the immune killing effect of host cells. It can survive for a long time and proliferate slowly in macrophages. When the host's immunity is low, dormant Mycobacterium tuberculosis can be reactivated, causing the body to develop active tuberculosis. After infection with Mycobacterium tuberculosis, the pathogen can remain dormant in the host for a long time or cause persistent infection, which has created a great obstacle to the treatment and prevention of the disease. In addition, the difficulty in treating tuberculosis at this stage also lies in multidrug-resistant and extensively drug-resistant tuberculosis. The lack of new tuberculosis drugs and the lack of basic research on Mycobacterium tuberculosis are the main reasons for the low cure rate of drug-resistant tuberculosis. Therefore, it is urgent to find new drug targets and develop new anti-tuberculosis drugs to treat tuberculosis.

[0003] According to the World Health Organization's "Global Tuberculosis Report" released in 2022, there are about 10 million new cases of tuberculosis worldwide each year, and the number of deaths from tuberculosis worldwide is about 1.4 million each year. At present, tuberculosis diagnosis still faces many technical difficulties, mainly in the following aspects: 1) Mycobacterium tuberculosis grows slowly and takes a long time to culture. 2) The detection technology is not sensitive enough and the detection method is not reliable enough. 3) High cost and susceptible to environmental influences. 4) The diagnosis is complex and difficult to diagnose in a timely and accurate manner. Tuberculosis antigen detection methods have been developed for many years and cover a variety of detection methods, including immunochromatographic test strips, enzyme-linked immunosorbent assay (ELISA), chemiluminescence, fluorescent immunoassay (FIA), etc. These antigen detection methods are based on the detection of tuberculosis antigens in patient body fluids or tissues, and are characterized by rapidity, accuracy, and sensitivity. However, these tuberculosis antigen detection methods still have great defects. The sensitivity and specificity of some test kits still have large errors. Other methods are expensive and require the introduction of equipment and technical cultivation, and have poor clinical applicability. Therefore, tuberculosis antigen detection technology needs to be further improved and developed, and it is urgent to develop a tuberculosis antigen detection method with high sensitivity, good specificity, easy use and low price.

[0004] C5orf24 is a gene on human chromosome 5q31.1 that encodes a protein consisting of approximately 188 amino acids. C5orf24 is a cellular transcriptional regulator that plays different functions in different cell types, including processes such as cell proliferation, cell polarization, migration, and tumor development. C5orf24 plays a variety of important functions in various physiological and pathological states of cells. C5orf24 can specifically and efficiently capture the characteristics of multiple tuberculosis antigens, and create a ligand protein capture method to detect tuberculosis antigens. Therefore, regulating the activity of C5orf24 will have an important impact on the body and may also play an important role in the prevention or treatment of certain diseases. An important way to regulate the activity of C5orf24 can be achieved through proteins that can directly interact with C5orf24. Therefore, proteins that can directly interact with C5orf24 will have important medicinal value and can be developed as protein or peptide drugs for the prevention or treatment of certain diseases. Summary of the invention

[0005] The present invention utilizes the ability of C5orf24 protein to simultaneously capture multiple tuberculosis antigens in tuberculosis patient specimens, and detects the ability to capture tuberculosis antigens by recombining C5orf24 protein and expressing and purifying it.

[0006] In a first aspect, the present invention provides a C5orf24 recombinant protein, wherein the C5orf24 recombinant protein has the ability to capture tuberculosis antigens, and the amino acid sequence of the C5orf24 recombinant protein is shown in SEQ ID NO.1.

[0007] SEQ ID NO.1:

[0008] MMHPVASSNPAFCGPGKPSCLNEDAMRAADQFDIYSSQQSKYSHTVNHKPMVCQRQDPLNETHLQTTSGRSIEIKDELKKKKNLNRSGKRGRPSGTTKSAGYRTSTGRPLGTTKAAGFKTSPGRPLGTTKAAGYKVSPGRPPGSIKALSRLADLGYGCGTAAFPYPMMHGRAVHGVEETSSEVKPPNE.

[0009] In a second aspect, the present invention provides a method for preparing a C5orf24 recombinant protein, the method comprising the following steps:

[0010] S1. Obtain the nucleotide sequence of C5orf24 protein, the nucleotide sequence is shown in SEQ ID NO.2,

[0011] S2. Load the nucleotide sequence obtained in step S1 into a specific vector to construct a recombinant plasmid,

[0012] S3. The recombinant plasmid constructed in step S2 is transfected into the strain for expression to obtain the recombinant protein of the present invention;

[0013] The C5orf24 recombinant protein of the present invention has the function of capturing tuberculosis antigens.

[0014] SEQ ID NO.2:

[0015] .

[0016] Furthermore, the vector includes but is not limited to one or more of pET-28a, pET-30a, pET-22b, pET-24a, and pET-32c, preferably pET-28a.

[0017] Furthermore, the strain is selected from E. coli BL21 (DE3).

[0018] In a third aspect, the present invention provides a kit for detecting Mycobacterium tuberculosis, the kit comprising a reagent for detecting Mycobacterium tuberculosis and instructions, the reagent further comprising a C5orf24 recombinant protein, and the C5orf24 recombinant protein has the ability to capture Mycobacterium tuberculosis antigens.

[0019] In a fourth aspect, the present invention provides a use of the C5orf24 recombinant protein as described in the first aspect in preparing a kit for detecting tuberculosis antigens, wherein the C5orf24 recombinant protein has the ability to capture tuberculosis antigens.

[0020] Furthermore, the tuberculosis antigen is selected from one or more of Rv0277c, Rv1838c, Rv1982c, Rv2098c, Rv3423c, and Rv3759c.

[0021] Beneficial effects:

[0022] The C5orf24 recombinant protein prepared by the present invention has the characteristics of being able to capture a variety of tuberculosis antigens specifically and efficiently, and can detect tuberculosis antigens by creating a ligand protein capture method. DETAILED DESCRIPTION

[0023] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0024] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0025] Capture: When proteins interact directly, they can be firmly bound together, which can also be described as one protein capturing another. When such proteins interact, they are mainly bound together by the following non-covalent forces: (1) Electrostatic interaction: the interaction between charged amino acid residues. (2) Van der Waals force: the short-range attraction between non-polar amino acid residues. (3) Hydrophobic interaction: non-polar residues gather in water to form a hydrophobic core, forming a hydrophilic-hydrophobic interaction. (4) Hydrogen bond: hydrogen bond interaction between polar residues.

[0026] Recombinant protein: Recombinant protein is the subject to be protected - ligand protein. If it is to be used in practice, it must have a corresponding ligand protein. There is no ready-made ligand protein in nature, so it can only be prepared (obtaining the relevant ligand protein through recombinant expression), which is an important part of practical application.

[0027] Tuberculosis antigen: It can be used as direct evidence of the etiology of tuberculosis and for the diagnosis and confirmation of tuberculosis. At the same time, after the patient's body is infected with Mycobacterium tuberculosis, tuberculosis antigen will first appear in the body and exist in the patient's body as the disease progresses. The detection of tuberculosis antigen is not affected by the host's immune function status and can be used as direct evidence of the existence of Mycobacterium tuberculosis for diagnosis and confirmation, avoiding false negatives in humoral immunity detection or cellular immunity detection due to weak antigenicity of Mycobacterium tuberculosis or low immune response of tuberculosis patients. The amount of tuberculosis antigen in the patient's body can also directly reflect the severity of his disease.

[0028] Example 1: Synthesis of C5orf24 protein encoding gene and construction of recombinant plasmid

[0029] The nucleotide sequence of C5orf24 protein was obtained and loaded into the vector pET-28a. Then sequencing confirmed that the pET-28a-C5orf24 protein expression plasmid was successfully constructed. The nucleotide sequence is shown in SEQ ID NO.2.

[0030] SEQ ID NO.2:

[0031] .

[0032] Example 2: Expression and purification of C5orf24 recombinant protein

[0033] The successfully constructed recombinant plasmid pET-28a-C5orf24 was transfected into E. coli BL21 (DE3) to express the recombinant protein. Under IPTG induction, the recombinant plasmid transformed bacteria successfully expressed the C5orf24 recombinant protein. After affinity purification by Ni-NTA-His column, a high-purity protein was obtained with a relative molecular weight of about 25 kDa, which was in line with the expected size. The amino acid sequence of the C5orf24 recombinant protein is shown in SEQ ID NO.1.

[0034] SEQ ID NO.1:

[0035] MMHPVASSNPAFCGPGKPSCLNEDAMRAADQFDIYSSQQSKYSHTVNHKPMVCQRQDPLNETHLQTTSGRSIEIKDELKKKKNLNRSGKRGRPSGTTKSAGYRTSTGRPLGTTKAAGFKTSPGRPLGTTKAAGYKVSPGRPPGSIKALSRLADLGYGCGTAAFPYPMMHGRAVHGVEETSSEVKPPNE

[0036] The concentration of C5orf24 was 1.506 mg / mL as determined by the BCA method.

[0037] Expression and purification of C5orf24 recombinant protein

[0038] 1) Inoculate the E. coli BL21 (DE3) strain containing the pET-28a-C5orf24 expression plasmid into 5 ml of LB liquid culture medium containing the corresponding resistance and culture at 37°C and 200 rpm.

[0039] 2) The next day, the strain was inoculated into 500 mL LB liquid medium (kanamycin concentration 50 μg / mL) at a ratio of 1:100, cultured at 37°C until OD = 0.4-0.6, 0.8 mM IPTG was added, and expression was induced at 25°C for 12 h. The cells were collected by centrifugation at 12000 rpm and 4°C for 15 min.

[0040] 3) The induced bacterial solution was centrifuged at 6000 rpm for 10 min, the supernatant was discarded, and the precipitate was resuspended in 200 ml of 500 mM NaCl 20 mM PBS pH 8.0 buffer.

[0041] 4) The resuspended bacteria were ultrasonically disrupted, and then centrifuged at 12000 rpm for 10 min, and the supernatant was collected for later use.

[0042] 5) Equilibrate the treated Ni column (GE) with 5 times more volume of Binding buffer (500mMNaCl 20mM PBS pH8.0) at a flow rate of 1-1.5ml / min, and adjust the baseline of the UV detector.

[0043] 6) Load the treated sample at a flow rate of 1 ml / min. Collect the flow-through, and after loading, use Binding buffer (500 mM NaCl 20 mM PBS pH 8.0) to wash the absorbance value of the UV detector to the baseline.

[0044] 7) Elute with washing buffer (500 mM NaCl 20 mM PBS pH 8.0 20 mM imidazole) and collect the elution peak.

[0045] 8) Elute with Elutionbuffer I (500 mM NaCl 20 mM PBS pH 8.0 60 mM imidazole) and collect the elution peak.

[0046] 9) Elute with ElutionbufferII (500 mM NaCl 20 mM PBS pH 8.0 300 mM imidazole) and collect the elution peak.

[0047] 10) The imidazole eluted fraction was dialyzed with 20 mM PBS pH 8.0 buffer to obtain the purified recombinant protein C5orf24, and its protein concentration was determined by BCA.

[0048] Example 3 Identification of tuberculosis antigens captured by C5orf24 recombinant protein by mass spectrometry

[0049] Taking advantage of the ability of C5orf24 recombinant protein to specifically and efficiently capture multiple tuberculosis antigens, a recombinant protein capture method was constructed to detect tuberculosis antigens in patient samples. C5orf24 recombinant protein specifically and efficiently captured multiple tuberculosis antigens, and biological mass spectrometry was used to identify the tuberculosis antigens captured by C5orf24 recombinant protein.

[0050] The specific method for identifying tuberculosis antigens captured by C5orf24 recombinant protein is as follows:

[0051] (1) Coating of C5orf24 recombinant protein: Dilute C5orf24 recombinant protein to 4 μg / ml with coating solution (0.05 mol / L carbonate buffer, pH 9.6), and add 100 μl of the diluted coating solution to each well of the ELISA plate. Place the ELISA plate in a humidified chamber and coat overnight at 4°C.

[0052] (2) Wash the plate to remove the liquid in the wells of the ELISA plate, then fill all the wells with washing buffer (0.15 mol / L pH 7.4 PBS containing 0.05% Tween-20), remove the washing solution, wrap it with absorbent paper and dry it, and wash the plate twice.

[0053] (3) Blocking: Add 250 μl of blocking solution (pH 9.6, 0.05 mol / L carbonate buffer containing 2.0% BSA) to each well of the ELISA plate, place the ELISA plate in a wet box, and incubate at 37°C for 2 h.

[0054] (4) Wash the plate to remove the blocking solution and wash twice using the same procedure as above.

[0055] (5) Add tuberculosis patient samples and incubate. First add 70 μl of sample diluent to the sample well on the ELISA plate, then add 30 μl of the sample to be tested. When adding the sample, add the sample to the bottom of the ELISA plate well, and try not to touch the well wall. Incubate at 37°C for 1.5 hours.

[0056] (6) Wash the plate to remove the sample solution from the wells of the ELISA plate and wash three times using the same procedure as above.

[0057] (7) Preparation of samples for mass spectrometry identification An appropriate amount of mass spectrometry grade trypsin solution was added to the wells of the ELISA plate and digested overnight at 37°C. After overnight, FA (formic acid) was added to a final concentration of 0.1% to terminate the digestion.

[0058] (8) Take 10ul of sample and load it onto the machine for detection using liquid chromatography-tandem mass spectrometry (LC-MS / MS, BGI Protein Research Center Co., Ltd.). The mass spectrometry data obtained by the detection were searched and analyzed using the MASCOT database (http: / / www.matrixscience.com / ). The tuberculosis antigens identified were: Rv0277c, Rv1838c, Rv1982c, Rv2098c, Rv3423c, and Rv3759c.

[0059] Example 4 Method for detecting Mycobacterium tuberculosis antigens

[0060] Taking advantage of the ability of C5orf24 recombinant protein to specifically and efficiently capture a variety of tuberculosis antigens, a ligand protein capture method was created to detect tuberculosis antigens. That is, the C5orf24 recombinant protein was used to coat the ELISA plate, which was then blocked and eluted; then the tuberculosis patient sample was added, incubated and eluted. At this time, the C5orf24 recombinant protein captured the specific tuberculosis antigen in the sample; then tuberculosis antibodies (HRP enzyme labeled) were added, incubated and eluted; then HRP enzyme substrate was added for color development. If the color development result is positive, it indicates tuberculosis infection, otherwise it is tuberculosis negative. This method is a method for detecting Mycobacterium tuberculosis infection, but it is not limited to this detection method. Other detection methods such as fluorescent test strip detection method or colloidal gold test strip detection method can also be used. The detection method of tuberculosis antigen in specific samples is as follows:

[0061] 1. Detection reagents for Mycobacterium tuberculosis antigens:

[0062] Antigen coating solution (0.05 mol / L carbonate buffer at pH 9.6), washing buffer (0.15 mol / L pH 7.4 PBS containing 0.05% Tween-20), blocking solution (0.05 mol / L carbonate buffer at pH 9.6 containing 2% BSA), diluent (washing buffer containing 0.1% BSA), 1:1000 diluted HRP-labeled rabbit anti-tuberculosis IgG antibody (catalog number ab21189, purchased from Shanghai Union Biotechnology Co., Ltd.), positive serum, negative serum, TMB-H2O2 substrate colorimetric solution [sodium hydrogen phosphate-citrate buffer (pH 5.5) containing TMB (tetramethylbenzidine)], and 2 mol / L sulfuric acid stop solution.

[0063] 2. Detection methods for Mycobacterium tuberculosis antigens

[0064] (1) Antigen coating: Dilute the C5orf24 recombinant protein to 4 μg / ml with coating solution, and add 100 μl of the diluted antigen solution to each well of the ELISA plate. Place the ELISA plate in a humidified chamber and coat overnight at 4°C.

[0065] (2) Wash the plate to remove the liquid from the wells of the ELISA plate, then fill all the wells with washing solution, remove the washing tower liquid, wrap it with absorbent paper and dry it, and wash the plate twice.

[0066] (3) Blocking: Add 250 μl of blocking solution (pH 9.6, 0.05 mol / L carbonate buffer containing 2.0% BSA) to each well of the ELISA plate, place the ELISA plate in a wet box, and incubate at 37°C for 2 h.

[0067] (4) Wash the plate to remove the blocking solution and wash twice using the same procedure as above.

[0068] (5) Add sample and incubate. First add 90 μl of sample diluent to the sample well on the ELISA plate, then add 10 μl of the sample to be tested (the final dilution of the sample is 10 times). When adding the sample, add the sample to the bottom of the well of the ELISA plate, and try not to touch the well wall. Incubate at 37°C for 1.5 hours.

[0069] (6) Wash the plate to remove the sample solution from the wells of the ELISA plate and wash three times using the same procedure as above.

[0070] (7) Add enzyme-labeled antibody for incubation. Dilute the enzyme-labeled antibody with antibody diluent (1:1000 dilution) and add 100 μl of the diluted enzyme-labeled antibody to each well, except for the blank well. Incubate in a 37°C wet box for 1 h.

[0071] (8) Wash the plate to remove the enzyme-labeled antibody solution and wash three times using the same procedure as above.

[0072] (9) Color development: Add 100 μl of color development solution to each well, gently shake to mix, and develop the color for 10 to 20 minutes at room temperature in the dark.

[0073] (10) After the color development is completed, add 50 μl of stop solution to each well to terminate the reaction (the blue color immediately turns yellow).

[0074] (11) Rapidly measure the absorbance (OD value) of each well of the ELISA plate at a wavelength of 450 nm using an ELISA reader (Note: use the blank well as the background for subtraction and zero adjustment). The measurement should be performed within 20 minutes after adding the stop solution.

[0075] Example 5: Detection of Mycobacterium tuberculosis infection

[0076] The detection reagent for Mycobacterium tuberculosis prepared by the above method was used to detect 110 sera of active tuberculosis patients and 37 sera of healthy people according to the above detection method; 102 samples of active tuberculosis patients were tested by Mycobacterium tuberculosis nucleic acid (PCR) detection as a comparison, and the test results are shown in Table 1.

[0077] Table 1 The positive rate of tuberculosis patients detected by different detection methods

[0078]

[0079]

[0080] As can be seen from the results in Table 1, the sensitivity of the detection method for Mycobacterium tuberculosis antigen in the detection of tuberculosis antigen in the serum of tuberculosis patients is 74.55%, which is significantly higher than the 54.9% of the Mycobacterium tuberculosis nucleic acid (PCR) detection method. The specificity of the detection method is 94.6% (1-5.4%=94.6%).

Claims

1. A kit for detecting Mycobacterium tuberculosis, the kit comprising a reagent for detecting Mycobacterium tuberculosis and instructions, the reagent further comprising a C5orf24 recombinant protein, the C5orf24 recombinant protein having the ability to capture Mycobacterium tuberculosis antigens, the amino acid sequence of the C5orf24 recombinant protein being as shown in SEQ ID NO.1, SEQ ID NO. 1: MMHPVASSNPAFCGPGKPSCLNEDAMRAADQFDIYSSQQSKYSHTVNHKPMVCQRQDPLNETHLQTTSGRSIEIKDELKKKKNLNRSGKRGRPSGTTKSAGYRTSTGRPLGTTKAAGFKTSPGRPLGTTKAAGYKVSPGRPPGSIKALSRLADLGYGCGTAAFPYPMMHGRAVHGVEETSSEVKPPNE.

2. Use of a C5orf24 recombinant protein in preparing a kit for detecting tuberculosis antigens, wherein the C5orf24 recombinant protein has the ability to capture tuberculosis antigens, and the tuberculosis antigens are selected from one or more of Rv0277c, Rv1838c, Rv1982c, Rv2098c, Rv3423c, and Rv3759c; the amino acid sequence of the C5orf24 recombinant protein is shown in SEQ ID NO.1, SEQ ID NO. 1: MMHPVASSNPAFCGPGKPSCLNEDAMRAADQFDIYSSQQSKYSHTVNHKPMVCQRQDPLNETHLQTTSGRSIEIKDELKKKKNLNRSGKRGRPSGTTKSAGYRTSTGRPLGTTKAAGFKTSPGRPLGTTKAAGYKVSPGRPPGSIKALSRLADLGYGCGTAAFPYPMMHGRAVHGVEETSSEVKPPNE.